FAQs

As at 31 December 2025, we employed approximately 96,100 people:

• 38% emerging markets
• 35% Europe
• 19% US
• 8% in Established Rest of World

Further details on employee can be found on page 27 of the latest Annual Report.

The total number of shares in issue as at 31 December 2025 was 1,550,907,927.

AstraZeneca PLC publishes its total number of voting rights each month. These notifications can be found in the Stock exchange announcements.

AstraZeneca Ordinary Shares are currently traded on the London Stock Exchange, Nasdaq Stockholm and the New York Stock Exchange. The symbol/ticker is AZN in all three markets.

AstraZeneca adheres to the International Financial Reporting Standards (IFRS) and International Accounting Standards (IAS) with appropriate conversion to US GAAP being shown in our financial statements.

Please visit our Debt Investors page for details of AstraZeneca’s current debt rating.

AstraZeneca reports in US dollars.

AstraZeneca was formed on 6 April 1999 through the merger of Astra AB of Sweden and Zeneca PLC of the United Kingdom.

This information can be found in the financial results section.

For information on dividends, please see the Dividends section of the FAQs.

Dividend policy

During 2021, AstraZeneca announced that from September 2021 the Company would stop making dividend payments by way of cheque. Dividends will only be paid by electronic methods.

Removal of cheques has a number of benefits. There is a positive environmental benefit through the reduction in dividend stationery. Shareholders also benefit from increased payment security and faster receipt of funds when payments are made electronically. In addition, the removal of cheque payments reduces administration for both AstraZeneca and shareholders and also reduces costs.

Shareholders will need to provide a bank mandate to receive their dividend payment directly into a bank or building society account. 

Shareholders can provide a bank mandate through Computershare’s shareholder portal, Investor Centre.

US Investor Center

UK Investor Centre

To register for Investor Centre, Shareholders will require their unique Shareholder Reference Number (SRN) which can be found on communications issued to them from Computershare.

Holders of shares traded on Stockholm Nasdaq should contact Euroclear on +46 (0) 8 402 9000. 

At present AstraZeneca does not have a dividend re-investment plan for Ordinary shareholders.

Please visit our dividend policy.

AstraZeneca pays the dividend in the currency corresponding to where the shares are listed.

Holdings in the Corporate Sponsored Nominee (CSN) listed on the London Stock Exchange may be able to use Computershare’s International Funds Transfer service to receive the dividend in a currency other than GBP. Shareholders can provide their international mandate through Computershare’s shareholder portal, Investor Centre.

Effective 17 November 2025, AstraZeneca’s Ordinary Share Registrar is Computershare Investor Services.

Shareholders can contact Computershare via WebCorres@computershare.co.uk and via the shareholder helplines below:

Computershare Investor Services PLC - UK Registrar (holding of Depository Interests (DI’s)

Tel no: (UK only) 0370 707 1682

Tel no: (outside the UK) +44 (0) 370 707 1682

Computershare Investor Services - US Registrar and Transfer Agent

Tel no: (US only) +1 (888) 697-8018

Tel no: (outside the US) +1 (781) 575-2844

------------------------------------------

Euroclear Sweden AB - Swedish Central Securities Depository

For holders of shares traded on Stockholm Nasdaq contact Euroclear on +46 (0) 8 402 9000

On 2 February 2026, AstraZeneca implemented its harmonised listing structure, and AstraZeneca’s Ordinary Shares are now listed directly on the London Stock Exchange, Nasdaq Stockholm and the New York Stock Exchange.  Further information is available here.

Effective 17 November 2025, AstraZeneca’s Ordinary Share Registrar is Computershare Investor Services.

Shareholders can contact Computershare via WebCorres@computershare.co.uk and via the shareholder helplines below:

Computershare Investor Services PLC - UK Registrar (holding of Depository Interests (DI’s)

Tel no: (UK only) 0370 707 1682

Tel no: (outside the UK) +44 (0) 370 707 1682

Computershare Investor Services - US Registrar and Transfer Agent

Tel no: (US only) +1 (888) 697-8018

Tel no: (outside the US) +1 (781) 575-2844

------------------------------------------

Euroclear Sweden AB - Swedish Central Securities Depository

For holders of shares traded on Stockholm Nasdaq contact Euroclear on +46 (0) 8 402 9000

------------------------------------------

If you have a historical query on the closed ADR facility, please contact EQ Shareowner Services on +1 800 697 8018 (toll free if calling within the US) or +1 651 453 2128 if calling from outside the US

From 2 February 2026, the way you hold your AstraZeneca shares may change.

AstraZeneca Ordinary Shares are now directly listed on the New York Stock Exchange (“NYSE”), in addition to our existing listings in the UK and Sweden. As part of this harmonisation, the American Depositary Receipts (“ADR”) facility has been closed.

Following completion of the Listing Harmonisation, Computershare will send you further information explaining what this means for your specific shareholding and any actions you may need to take.

If you have any questions, you can contact Computershare via the following channels:

• Online: www.computershare.com/uk/investor-centre
• Phone: 0370 707 1682 (UK) or +44 370 707 1682 (international)
• Email: WebCorres@computershare.co.uk

If you have a historical query on the closed ADR facility, please contact EQ Shareowner Services on +1 800 697 8018 (toll free if calling within the US) or +1 651 453 2128 if calling from outside the US.”

Please follow the link below to a summary of dividends paid in the form of Syngenta shares.

View UK cost basis information (opens in a new window).

Please follow the link below to a summary of dividends paid in the form of Syngenta shares.

View US cost basis information (opens in a new window).

View a letter to Astra AB shareholders (opens in a new window).

A legal representative, Peter Haglund, has been appointed to act on behalf of minority shareholders. He can be contacted at Advokatfirman Sodermark, Box 14055, SE 104 40 Stockholm, Sweden, telephone +46 8 670 57 50 and fax +46 8 663 67 20.

On 6 April 1999 (the first trading day of AstraZeneca PLC) the closing price was GBP 29.46.

Shares in Zeneca Group PLC acquired on demerger from ICI will be treated as having a base cost for capital gains tax purposes ascertained by reference to the values of Zeneca and ICI shares on 1 June 1993 calculated in accordance with the provisions of Section 272 of the Taxation of Chargeable Gains Act 1992. The base cost of any holding of ICI Shares on that date will be adjusted on the same basis.

The relevant prices on The London Stock Exchange on 1 June 1993 were:

Zeneca - 625.75p and ICI - 631.75p

The base cost of the pre-merger ICI Shares were therefore split between the post-demerger Zeneca and ICI Shares in the following proportions:

Zeneca - 0.49761 and ICI - 0.50239

Astra AB and Zeneca Group PLC shares were merged on 6th April 1999.
1 Astra share : 0.5045 AstraZeneca share
1 Zeneca share : 1 AstraZeneca share

AstraZeneca demerged its agrochemical business on 13 November 2000.

A ‘Boiler Room’ fraud may take different forms but typically involves the use of high-pressure sales techniques and the promise of opportunities that appear too good to be true. AstraZeneca shareholders may be targeted by unsolicited phone calls or correspondence from ‘brokers’ who are often based overseas concerning investments and promising high financial returns. Unfortunately, the high profits promised never materialise and shareholders are often left significantly out of pocket. The ‘brokers’ are often both persistent and extremely persuasive with even experienced investors falling victim to the scams. This type of fraud is called ‘boiler room’ fraud because of the high pressure sales techniques used by the ‘brokers’. Around 5,000 people contact the Financial Conduct Authority (the ‘FCA’) each year regarding share fraud with victims losing an average of £20,000.

AstraZeneca shareholders are advised to be extremely cautious of any unsolicited approaches offering advice, free reports and offers to buy shares at a discount or sell at an inflated price.

In the event that you receive unsolicited contact regarding an investment opportunity the FCA offers the following advice, full details of which can be found on their website:

• Reject any cold calls
• Take the name of the person that has contacted you along with the full name and address of the organisation which they purport to work for
• Check that the firm is correctly authorised by searching the FCA Register. The FCA strongly advise that individuals should only deal with financial services firms that are properly authorised by the FCA. You should verify the call using the contact details provided on the FCA Register
• If you deal with an unauthorised firm you will not be eligible to receive payment under the Financial Services Compensation Scheme or have access to the Financial Ombudsman Service
• Check whether the firm appears on the FCA Warning List
• Seek impartial advice from a financial adviser before you make an investment
• If a firm does not appear on the FCA Register or you are told by the ‘broker’ that the details are out of date contact the FCA on 0800 111 6768 or use the FCA reporting form which can be found here

If you believe that you have already paid money to share fraudsters you should contact ActionFraud on +44(0)300 123 2040.

Where can I find further information?

Further information on Boiler Room and share frauds can be found on the FCA website and on the ActionFraud website.

Further information on Boiler Room and share frauds can be found on the FCA website and on the Action Fraud website.